Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Clinical significance of detection of mononuclear phagocyte subsets in blood and bronchoalveolar lavage fluid (BALF) in pulmonary sarcoidosis

View through CrossRef
This study aimed to investigate the clinical significance of the detection of mononuclear phagocytes subsets in pulmonary sarcoidosis blood and bronchoalveolar lavage fluid (BALF). For this purpose, a total of 52 patients with pulmonary sarcoidosis were selected as the study group, 52 healthy people served as the “NC Group a” (peripheral blood mononuclear cell control group), 47 patients with chronic cough and no pulmonary sarcoidosis who underwent bronchoscopy were used as “control group b” (alveolar lavage fluid macrophage control group). Fasting peripheral blood and BALF were collected, and flow cytometry was used to detect monocytes and macrophage subpopulations. The monocytes and macrophage subpopulations of the study group were compared before and after treatment. The results showed that the proportion of CD14++CD16- subgroup of patients with pulmonary sarcoidosis was lower than that of healthy people (74.21±4.10% vs 84.32±4.76%); The proportion of CD14++CD16+ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people (7.42±4.08% vs 3.95±1.94%); The proportion of CD14+CD16++ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people in the control group, but the difference was not significant. After 2 months of treatment, the proportion of CD14++CD16- subgroups in peripheral blood mononuclear cells increased, and the proportion of CD14++CD16+ subgroups decreased. The proportion of M1 in patients with pulmonary sarcoidosis was lower than that in patients with non-pulmonary nodules (24.32±11.36% vs 47.03±13.86%); the proportion of M2 in patients with pulmonary sarcoidosis was higher than the proportion of M2 in patients with non-pulmonary nodules (75.40±10.23% vs 52.53±12.01%). After treatment, the proportion of M1 of BALF macrophages in patients with pulmonary sarcoidosis was increased (P<0.05), and the proportion of M2 was reduced (P<0.05). In general, detection of changes in peripheral blood mononuclear cell subpopulations and BALF macrophage subpopulations in patients with pulmonary sarcoidosis has certain clinical significance for the treatment.
Title: Clinical significance of detection of mononuclear phagocyte subsets in blood and bronchoalveolar lavage fluid (BALF) in pulmonary sarcoidosis
Description:
This study aimed to investigate the clinical significance of the detection of mononuclear phagocytes subsets in pulmonary sarcoidosis blood and bronchoalveolar lavage fluid (BALF).
For this purpose, a total of 52 patients with pulmonary sarcoidosis were selected as the study group, 52 healthy people served as the “NC Group a” (peripheral blood mononuclear cell control group), 47 patients with chronic cough and no pulmonary sarcoidosis who underwent bronchoscopy were used as “control group b” (alveolar lavage fluid macrophage control group).
Fasting peripheral blood and BALF were collected, and flow cytometry was used to detect monocytes and macrophage subpopulations.
The monocytes and macrophage subpopulations of the study group were compared before and after treatment.
The results showed that the proportion of CD14++CD16- subgroup of patients with pulmonary sarcoidosis was lower than that of healthy people (74.
21±4.
10% vs 84.
32±4.
76%); The proportion of CD14++CD16+ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people (7.
42±4.
08% vs 3.
95±1.
94%); The proportion of CD14+CD16++ subgroups of patients with pulmonary sarcoidosis was higher than that of healthy people in the control group, but the difference was not significant.
After 2 months of treatment, the proportion of CD14++CD16- subgroups in peripheral blood mononuclear cells increased, and the proportion of CD14++CD16+ subgroups decreased.
The proportion of M1 in patients with pulmonary sarcoidosis was lower than that in patients with non-pulmonary nodules (24.
32±11.
36% vs 47.
03±13.
86%); the proportion of M2 in patients with pulmonary sarcoidosis was higher than the proportion of M2 in patients with non-pulmonary nodules (75.
40±10.
23% vs 52.
53±12.
01%).
After treatment, the proportion of M1 of BALF macrophages in patients with pulmonary sarcoidosis was increased (P<0.
05), and the proportion of M2 was reduced (P<0.
05).
In general, detection of changes in peripheral blood mononuclear cell subpopulations and BALF macrophage subpopulations in patients with pulmonary sarcoidosis has certain clinical significance for the treatment.

Related Results

[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED]Guardian Blood Balance Reviews (Works Or Hoax) Does Guardian Botanicals Blood Balance AU Really Works? Read Updated Report! Diabetes and Hypertension is such a health p...
Antimycobacterial immune responses in patients with pulmonary sarcoidosis
Antimycobacterial immune responses in patients with pulmonary sarcoidosis
AbstractIntroduction:  Sarcoidosis is a multisystem granulomatous disease of unknown origin. Pathogenetic involvement of Mycobacterium tuberculosis has frequently been discussed in...
Cytokine concentrations in bronchoalveolar lavage fluid (BALF) from children with severe community-acquired pneumonia (SCAP) from Shanghai
Cytokine concentrations in bronchoalveolar lavage fluid (BALF) from children with severe community-acquired pneumonia (SCAP) from Shanghai
Background: It has been well known that overreaction of host immune systems plays a critical role in severe community-acquired pneumonia (SCAP). However, few of previous studies fo...
Inflammatory markers and pulmonary granuloma infiltration in sarcoidosis
Inflammatory markers and pulmonary granuloma infiltration in sarcoidosis
AbstractBackground and objectivePrevious studies have demonstrated increases of inflammatory mediators in sarcoidosis while epidemiological studies have also demonstrated an associ...
Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database
Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database
AbstractBackgroundThere is a documented association between drug exposure and sarcoidosis‐like reactions. In this study, we used the largest pharmacovigilance database to describe ...
Sarcoidosis
Sarcoidosis
Sarcoidosis is a systemic disease characterized by the presence of noncaseating granulomas, which accumulate in affected organs. The incidence, organ involvement, and disease sever...
Sarcoidosis
Sarcoidosis
Sarcoidosis is a systemic disease characterized by the presence of noncaseating granulomas, which accumulate in affected organs. The incidence, organ involvement, and disease sever...
Sarcoidosis: Pathogenesis, Diagnosis, and Clinical Management
Sarcoidosis: Pathogenesis, Diagnosis, and Clinical Management
Introduction: Sarcoidosis is a multisystem inflammatory disease of unknown etiology. It is more common in women and in people suffering from obesity.  A characteristic feature is t...

Back to Top